RankAlpha logo
Back to Rankings

BAX

Baxter InternationalC
NYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
View Chart
Current thesis
Five-percent organic sales growth across all segments, a raised 2026 outlook and positive free cash flow indicate improving stabilization. Resolution of the Novum IQ hold and durable margin recovery could support re-rating toward or above the supplied $27.60 analyst median target [#SEC-8K-2026-07-30].
Posture
Mixed
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-10-29 · BMO.
What can break
A prolonged Novum IQ LVP shipment and installation hold could weaken Infusion Systems revenue and hospital confidence.
Momentum
69
Value
60
Sentiment
47
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $25.00 · Bull $30.00 · Bear $18.00Analysis 2026-09-18; returns require an exact persisted reference.
Earnings
2026-10-29 · BMO
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-18 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-23

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions

Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $26.82
Why
Momentum69 · Δ7d +19.6
Value60 · Δ7d +0.2
Sentiment47 · Δ7d +0.1
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.

Confirming evidence

  • • Next scheduled catalyst: earnings 2026-10-29 · BMO.
  • • Value remains the lead driver in the composite, 7D delta +0.2.

Contradictions & invalidation

  • • A prolonged Novum IQ LVP shipment and installation hold could weaken Infusion Systems revenue and hospital confidence.
  • • Balance-sheet strengthening remains an execution objective; the $600 million cash tender reduces debt but consumes liquidity.
  • • The earnings beat benefited from a nonrecurring $0.11-per-share tariff refund, adjusted EPS declined year over year, and higher-cost inventory plus the Novum IQ hold remain execution headwinds.

Catalyst clock

2026-10-29 · BMO

Upsized debt tender execution

Lead driver: Value · See fundamentals
Momentum
69
8% active weight
Current posture
7d trendImproving
Δ7d
+19.6
Δ21d
+37.3
Value
60
47% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
-0.4
Sentiment
47
45% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-16.3
Why this grade

Composite grade C. Momentum 68.7 / Value 59.8 / Sentiment 47.5

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-18. Scenario method

B+
Bull case
30%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-09-18 · RankAlpha Sentiment Codex
Most likely
B
Base case
50%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-09-18 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-09-18 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$13.08B
Beta
0.58
Shares Out
517M
P/E (TTM) · Derived
-12.3
P/S (TTM)
0.93
P/FCF (TTM)
73.33
Rev YoY
+5.3%
EPS YoY
+11.6%
Gross Margin
+31.8%
Op Margin
+5.6%
Net Debt
$7.81B
Current Ratio
1.95
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data